Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Table 1

Patient baseline demographics and clinical characteristics.

		Patient demographics and clinical characteristics ( patients, 25 eyes)
Gender		13 female/8 male
Age (years)	Median (min–max)	64 (33–83)
Diabetes	Type 1, n (%)	2 (9.6)
	Type 2, n (%)	19 (90.4)
Insulin/ODT/ODT + insulin (n)		12/3/6
HbA1c levels (%)	Median (min–max)	8.3 (7.5–10.7)
High blood pressure, n (%)		18 (78.3)
Pan retinal photocoagulation, n (%)		20 (75), 2 ongoing
Lens; Status, n (%)	Phakic	12 (48)
	IOL	13 (52)
Ranibizumab ()	Median number of injections (min–max)	9.5 (3–15)
Ozurdex only ()	Median number of dexamethasone injections	1
Ranibizumab + Ozurdex ()	Median number of dexamethasone injections (min–max)	1 (1–3)
Macular laser history (n)		2

ODT: oral diabetes treatment.